Hypnotic medication in the treatment of chronic insomnia: Non nocere! Doesn't anyone care?

Sleep Medicine Reviews

Volumn 4, Issue 6, 2000, Pages 529-541

  Kramer, Milton ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidrug attitude; Clinical case series; Hypnotic drugs; Insomnia; Long term use; Pharmacological calvinism.; Sleeping pills

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CLONAZEPAM; DOXEPIN; HYPNOTIC AGENT; LOPRAZOLAM; METHYLPHENIDATE; PROTRIPTYLINE; TRAZODONE; TRIAZOLAM; TRYPTOPHAN;

AMNESIA; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; DAILY LIFE ACTIVITY; DATA BASE; DEATH; DEPRESSION; DISEASE ASSOCIATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG WITHDRAWAL; FALLING; HUMAN; INSOMNIA; QUALITY OF LIFE; RECURRENT DISEASE; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR;

EID: 0034487392     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1053/smrv.2000.0122     Document Type: Review

References (66)

1. An 87-year-old woman taking a benzodiazepine
2. Should benzodiazepines in an 87-year-old woman be tapered and discontinued?
3. In reply: Should benzodiazepines in an 87-year-old woman taking a benzodiazepine be tapered and discontinued?
4. An 87-year-old woman taking a benzodiazepine. 1 year later
5. Insomnia: Drug treatment
6. Current concepts: Management of insomnia
7. Mortality hazard associated with prescription hypnotics
8. Guidelines for the rational use of benzodiazepines. When and what to use
9. Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Durvey. 1
10. Insomnia and its treatments, prevalence and correlates
11. Side-effect "tolerance" in elderly recipients of benzodiazepine hypnotics
12. Patterns of benzodiazepine use in Great Britain as measured by a population survey
13. Prevalence and treatment of insomnia in general practice. A longitudinal study
14. Hypnotic drug use in Spain: A national study based on a network of community pharmacies. Spanish group for the study of hypnotic drug utilization
15. Epidemiological study of insomnia in the general population
16. The beneficial and adverse effects of hypnotics
17. New epidemiologic findings about insomnia and its treatment
18. Prevalence and heath consequences of insomnia
19. Daytime consequences and correlates of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. II
20. Quality of life in people with insomnia
21. Nonpharmacological interventions for insomnia: A metaanalysis of treatment efficacy
22. Benzodiazepines and zolpidem for chronic insomnia: A metaanalysis of treatment efficacy
23. Behavioral and pharmacological treatment for insomnia. In reply: Letter to the editor
24. The diagnosis and management of insomnia
25. Symptomatic treatment of insomnia
26. Long-term efficacy and tolerability of a new hypnoticloprazolam
27. Clinical uses and advantages of low doses of benzodiazepine hypnotics
28. Treatment of insomnia in the elderly
29. Rational use of benzodiazepines in the elderly
30. Incidence and remission of insomnia among elderly adults: An epidemiologic study of 6,800 persons over three years
31. Falls, hypnotics and altering physician prescribing practice
32. Efficacy and safety of hypnotic medications
33. Behavioral and pharmacological therapies for late-life insomnia
34. Anxiety or depression during withdrawal of hypnotic treatments
35. Psychtropic drugs: Long term use, dependency and the gender factor
36. The consistency of sleep measures
37. Tolerance studies with brotizolam in hospitalized patients
38. Hypnotic efficacy of temazepam: A long-term sleep laboratory evaluation
39. Long-term hypnotic efficacy and safe efficacy triazolam and flurazepam
40. Benzodiazepine hypnotics remain effective for 24 weeks
41. Report of the institute of medicine committee on the efficacy and safety of halcion
42. A controlled study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects
43. Listening to prozac but hearing placebo: A metaanalysis of antidepressant medication
44. Listening to meta-analysis but hearing bias
45. The need for perspective in evidence based medicine
46. Specific effects of sedative/hypnotic drugs in the treatment of incapacitating chronic insomnia
47. Triazolam: A review of its pharmacological properties and therapeutic efficacy in patients with insomnia
48. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in insomnia
49. The safety and efficacy of zolpidem in insomniac patients: A long-term open study in general practice
50. Long-term nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults
51. The effectiveness of sleeping medication in chronic insomnia: A clinical case series
52. A sleep clinic within a general hospital psychiatry services
53. Trends in the pharmacological treatment of insomnia
54. Long-term medicinal treatment of insomnia: A follow up study
55. Epidemiologic study of sleep disturbances and psychiatric disorders: An opportunity for prevention
56. Behavioral treatment of insomnia: A follow up study
57. Behavioral treatment of chronic insomnia in psychiatrically ill patients
58. Psychiatrists and internists beliefs about benzodiazepines
59. Antibiotic and benzodiazepine prescribing by general practice trainees
60. Educational visiting and hypnosedative prescribing in general practice
61. Commentary: Long-term use of sedative and hypnotic medication
62. Long-term follow-up of chronic insomnia
63. Chronic hypnotic use: Deadly risks, doubtful benefit
64. Treating insomnia in older adults: Taking a long-term view